OPHARMIC TECHNOLOGY
  • About
  • Technology
    • MeticTouch
  • Partnering
  • News
  • Careers
  • Contact

Vertical Divider
MeticTouch
First-in-Class Ocular Drug Delivery System
With over than 600 million patients worldwide [1], intravitreal injection is currently one of the most common treatment practice for a wide range of retinal diseases.

Opharmic’s first product, the MeticTouch, is designed with a specific focus on safety, non-invasiveness, and effectiveness in delivering therapeutics for anterior and posterior eye diseases treatment
.
[1] World Report on Vision, World Health Organisation, 2019
Clinical Impacts 
Opharmic's MeticTouch system offers non-invasive and effective ocular treatments with targeted drug delivery​.

Highly reducing patient discomfort and fear as well as eliminating risks of procedural and post-operative complications, Opharmic's treatment procedure saves up to 80% of time needed in drug administration in comparison to the conventional eye injection. 

Based on over a decade of research, safety, efficacy, and drug bioavailability of the patented technology behind the system is well-demonstrated in preclinical studies. 

Support

About Opharmic
Technology 
Partnering
News & Media
© COPYRIGHT 2022. ALL RIGHTS RESERVED.
  • About
  • Technology
    • MeticTouch
  • Partnering
  • News
  • Careers
  • Contact